The anticancer effects of thymol on HepG2 cell line

Area of Science:

• Hepatocellular carcinoma research
• Natural compound effects on cancer cells
• Oxidative stress and apoptosis mechanisms

Background:

• Liver cancer (hepatocellular carcinoma) incidence is rising globally.
• Thymol, a natural compound, is being investigated for its biological activities.
• Understanding thymol's effects on cancer cells is crucial for potential therapeutic strategies.

Purpose of the Study:

• To evaluate thymol's cytotoxic, genotoxic, apoptotic, oxidant, and antioxidant effects on hepatocellular carcinoma (HepG2) cells.
• To assess thymol's impact on healthy cells (HUVEC).
• To investigate thymol's role in oxidative stress and apoptosis pathways.

Main Methods:

• Cytotoxicity assessed using XTT assay.
• Oxidative stress measured via Total Oxidant Status (TOS) and Total Antioxidant Status (TAS) kits.
• Apoptosis detected by flow cytometry and Annexin V staining.
• Genotoxicity evaluated using the comet assay.
• Apoptotic gene expression analyzed by real-time PCR.

Main Results:

• Thymol's IC50 dose was 11 μM on HepG2 cells, with no significant toxicity to HUVEC cells.
• Thymol decreased TOS and increased TAS in HepG2 cells, indicating reduced oxidative stress.
• Thymol significantly induced apoptosis in HepG2 cells (21% vs. 1% in control).
• Genotoxicity was observed, evidenced by increased tail length in the comet assay.
• Thymol did not alter the expression of key apoptosis-related genes (bax, bcl-2, casp3).

Conclusions:

• Thymol exhibits a dual effect on hepatocellular carcinoma cells: it reduces oxidative stress and induces apoptosis.
• Despite therapeutic potential, thymol demonstrates genotoxic effects on HepG2 cells.
• Further investigation is warranted to balance thymol's anti-cancer properties with its genotoxic risks.